Cassava Sciences, Inc. (SAVA)
Automate Your Wheel Strategy on SAVA
With Tiblio's Option Bot, you can configure your own wheel strategy including SAVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SAVA
- Rev/Share 0.0
- Book/Share 2.6442
- PB 0.8131
- Debt/Equity 0.0
- CurrentRatio 9.0769
- ROIC -1.1895
- MktCap 103861985.0
- FreeCF/Share -2.2635
- PFCF -0.9508
- PE -1.4256
- Debt/Assets 0.0
- DivYield 0
- ROE -0.4629
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SAVA | H.C. Wainwright | Neutral | Buy | -- | $116 | Oct. 8, 2024 |
News
Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
As SVP, Neuroscience, Dr. Bordey will lead Cassava's ongoing research and development efforts Dr. Bordey to direct the scientific evaluation of simufilam in TSC-related epilepsy, and potentially additional pipeline indications AUSTIN, Texas, May 01, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President (SVP), Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis. Dr. Bordey will be primarily responsible …
Read More
Is the Future Bleak for SAVA Stock Following Another Setback?
Published: March 31, 2025 by: Zacks Investment Research
Sentiment: Negative
The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with uncertain growth prospects.
Read More
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Negative
Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints in the second late-stage study.
Read More
Cassava Sciences Discontinues Developing Simufilam For Alzheimer's After Another Phase 3 Trial Flop
Published: March 25, 2025 by: Benzinga
Sentiment: Negative
Cassava Sciences Inc. SAVA on Tuesday shared topline results from the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate Alzheimer's disease.
Read More
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128597&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit - SAVA
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128562&wire=1 or contact Joseph E. Levi, Esq.
Read More
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before February 10, 2025 to Discuss Your Rights – SAVA
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128534&wire=1 or contact Joseph E. Levi, Esq.
Read More
SAVA LAWSUIT ALERT: Levi & Korsinsky Notifies Cassava Sciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128502&wire=1 or contact Joseph E. Levi, Esq.
Read More
SAVA Deadline Today: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit
Published: February 10, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period"), of the important February 10, 2025 lead plaintiff deadline. So what: If you purchased Cassava securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Cassava Sciences, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SAVA
Published: February 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cassava Sciences, Inc. ("Cassava Sciences, Inc." or the "Company") (NASDAQ: SAVA) of a class action securities lawsuit.
Read More
FINAL REMINDER SAVA DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Cassava Sciences, Inc. Investors to Participate in the Class Action Lawsuit
Published: February 10, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or "the Company") (NASDAQ:SAVA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024 and November 24, 2024, both dates inclusive (the "Class Period").
Read More
Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA
Published: February 10, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA). Shareholders who purchased shares of SAVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Class Action Filed Against Cassava Sciences, Inc. (SAVA) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: February 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128314&wire=1 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Notifies Shareholders of Cassava Sciences, Inc.(SAVA) of a Class Action Lawsuit and an Upcoming Deadline
Published: February 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128311&wire=1 or contact Joseph E. Levi, Esq.
Read More
SAVA DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA
Published: February 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024, both dates inclusive (the “Class Period”), of the important February 10, 2025 lead plaintiff deadline.
Read More
February 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SAVA
Published: February 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cassava-sciences-inc-lawsuit-submission-form?prid=128299&wire=1 or contact Joseph E. Levi, Esq.
Read More
About Cassava Sciences, Inc. (SAVA)
- IPO Date 2000-07-14
- Website https://www.cassavasciences.com
- Industry Biotechnology
- CEO Mr. Richard Jon Barry
- Employees 30